Spots Global Cancer Trial Database for velcade
Every month we try and update this database with for velcade cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER) | NCT00473590 | Multiple Myelom... | Bevacizumab Bortezomib placebo | 18 Years - | Genentech, Inc. | |
| Quality of Life in Multiple Myeloma Patients Treated With Bortezomib | NCT01021592 | Multiple Myelom... | bortezomib | 18 Years - | Janssen Korea, Ltd., Korea | |
| PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma | NCT00319865 | Multiple Myelom... | Velcade Thalidomide Adriamycin Dexamethasone | 0 Years - 75 Years | Korean Multiple Myeloma Working Party | |
| Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone | NCT01237249 | Multiple Myelom... | Melphalan Prednisone Velcade Revlimid Dexamethasone | 65 Years - | PETHEMA Foundation | |
| Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients | NCT00500422 | Solid Tumors | Doxil Gemcitabine Velcade | - | M.D. Anderson Cancer Center | |
| Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients | NCT00500422 | Solid Tumors | Doxil Gemcitabine Velcade | - | M.D. Anderson Cancer Center | |
| A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma | NCT02268890 | Multiple Myelom... | Bortezomib | 20 Years - | Johnson & Johnson Taiwan Ltd | |
| A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | NCT01266811 | Multiple Myelom... | Placebo, Velcad... Siltuximab, Vel... | 18 Years - | Centocor, Inc. | |
| Study of Erlotinib in Combination With Bortezomib | NCT00895687 | Advanced Cancer | Erlotinib Hydro... Bortezomib | - | M.D. Anderson Cancer Center | |
| First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade | NCT01215344 | Multiple Myelom... | VELCADE Lenalidomide Dexamethasone DVT prophylaxis Bisphosphonates Liposomal doxor... Dexamethasone | 18 Years - 70 Years | Vanderbilt-Ingram Cancer Center | |
| Study of Temsirolimus, Topotecan, and Bortezomib | NCT00770731 | Advanced Cancer | Torisel (Temsir... Hycamtin (Topot... Velcade (Bortez... | - | M.D. Anderson Cancer Center | |
| Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma | NCT01029730 | Lymphoma | Bendamustine Bortezomib Rituximab | 18 Years - | SCRI Development Innovations, LLC | |
| Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients. | NCT01026701 | Multiple Myelom... | bortezomib | 18 Years - | Janssen Korea, Ltd., Korea | |
| Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma | NCT01186458 | Lymphoma, Non-H... | Fludarabine Velcade Rituximab | 18 Years - | Hoosier Cancer Research Network | |
| Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma | NCT00439361 | Hodgkin Lymphom... Lymphoma | Bortezomib Carboplatin Etoposide Ifosfamide Mesna | 16 Years - | M.D. Anderson Cancer Center | |
| Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | NCT04975997 | Multiple Myelom... | Dexamethasone Daratumumab Bortezomib Iberdomide Iberdomide Iberdomide | 18 Years - | Celgene | |
| A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma | NCT01801436 | Multiple Myelom... | Bortezomib | 18 Years - 65 Years | Johnson & Johnson Taiwan Ltd | |
| Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy | NCT00104871 | Insular Thyroid... Recurrent Thyro... Stage II Follic... Stage II Papill... Stage IV Follic... Stage IV Papill... | Bortezomib | 18 Years - | National Cancer Institute (NCI) | |
| Study of Erlotinib in Combination With Bortezomib | NCT00895687 | Advanced Cancer | Erlotinib Hydro... Bortezomib | - | M.D. Anderson Cancer Center | |
| Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma | NCT02145715 | Multiple Myelom... | Velcade Thalidomide Dexamethasone Panobinostat | 18 Years - | University of Leeds | |
| Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma | NCT00153920 | Multiple Myelom... | bortezomib | 18 Years - | Dana-Farber Cancer Institute | |
| Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy | NCT00343720 | Non-Small Cell ... | VELCADE Alimta | 18 Years - | Millennium Pharmaceuticals, Inc. | |
| A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma | NCT00401843 | Multiple Myelom... | Siltuximab Bortezomib Placebo Dexamethasone | 18 Years - 99 Years | Janssen Research & Development, LLC | |
| Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM) | NCT00422799 | Waldenstrom's M... | Bortezomib Rituximab | 18 Years - | Dana-Farber Cancer Institute | |
| Bortezomib-Dexamethasone-Doxorubicin-Study | NCT00401804 | Multiple Myelom... Renal Insuficie... | Dexamethasone, ... | 18 Years - | Austrian Forum Against Cancer | |
| Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia | NCT00142129 | Waldenstrom's M... Lymphoplasmacyt... | Bortezomib (Vel... | 18 Years - 90 Years | Dana-Farber Cancer Institute | |
| Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | NCT00337506 | Multiple Myelom... | Dexamethasone velcade | 18 Years - 75 Years | Nantes University Hospital | |
| Study of Mantle Cell Lymphoma Treatment by RiBVD | NCT01457144 | Mantle Cell Lym... | RiBVD | 65 Years - 85 Years | French Innovative Leukemia Organisation | |
| Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients | NCT00984828 | Multiple Myelom... | velcade | 18 Years - 65 Years | Shanghai Jiao Tong University School of Medicine | |
| Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma | NCT01186458 | Lymphoma, Non-H... | Fludarabine Velcade Rituximab | 18 Years - | Hoosier Cancer Research Network | |
| Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma | NCT01729338 | Multiple Myelom... | Velcade Cyclophosphamid... Revlimid | 18 Years - | Duke University | |
| Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma | NCT01040871 | Diffuse Large B... | VELCADE Rituximab Cyclophosphamid... Doxorubicin Prednisone Vincristine | 18 Years - | Millennium Pharmaceuticals, Inc. | |
| An Observational Study of Chinese Multiple Myeloma Patients Treated With Velcade | NCT01675245 | Multiple Myelom... | No intervention | - 18 Years | Xian-Janssen Pharmaceutical Ltd. | |
| VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates | NCT00320476 | Multiple Myelom... | Velcade | 65 Years - 75 Years | Korean Multiple Myeloma Working Party | |
| Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab | NCT00850499 | Follicular Lymp... | fludarabine rituximab VELCADE | 18 Years - | Millennium Pharmaceuticals, Inc. | |
| Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma | NCT01376401 | Multiple Myelom... | Bendamustine Velcade Prednisone | - | PETHEMA Foundation | |
| A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma | NCT00401843 | Multiple Myelom... | Siltuximab Bortezomib Placebo Dexamethasone | 18 Years - 99 Years | Janssen Research & Development, LLC | |
| Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL) | NCT00440726 | Acute Lymphobla... | Bortezomib Dexamethasone PEG-asparaginas... Doxorubicin Cytarabine Methotrexate Vincristine Triple IT Thera... | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients | NCT01720043 | Multiple Myelom... | Velcade | 18 Years - | University of Utah | |
| Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL) | NCT01236391 | Mantle Cell Lym... | PCI-32765 | 18 Years - | Pharmacyclics LLC. | |
| Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma | NCT01438177 | Multiple Myelom... | Velcade Cyclophosphamid... Chloroquine | 18 Years - | NYU Langone Health | |
| Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia | NCT00142129 | Waldenstrom's M... Lymphoplasmacyt... | Bortezomib (Vel... | 18 Years - 90 Years | Dana-Farber Cancer Institute | |
| Low Dose Melphalan and Bortezomib for AML and High-Risk MDS | NCT00789256 | Acute Myelogeno... Myelodysplastic... | Melphalan Bortezomib Melphalan and b... | - | Dartmouth-Hitchcock Medical Center | |
| Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma | NCT01729338 | Multiple Myelom... | Velcade Cyclophosphamid... Revlimid | 18 Years - | Duke University | |
| STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA | NCT03829371 | Multiple Myelom... | Velcade Melphalan Prednisone Lenalidomide Dexamethasone Daratumumab | 65 Years - | University of Turin, Italy | |
| Retrospective Survey of Re-treatment With Bortezomib | NCT01524445 | Hematological C... Multiple Myelom... | bortezomib retr... | 18 Years - | Janssen Pharmaceutica N.V., Belgium | |
| VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features | NCT00117351 | Carcinoma, Non-... Adenocarcinoma,... | VELCADE | 18 Years - | Millennium Pharmaceuticals, Inc. | |
| Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma | NCT00810576 | Lymphoma | Vorinostat Bortezomib | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy | NCT00833560 | Multiple Myelom... | Cyclophosphamid... Bortezomib Dexamethasone | 18 Years - 60 Years | Janssen-Cilag G.m.b.H | |
| UARK 2003-33, Total Therapy III | NCT00081939 | Multiple Myelom... | Velcade Thalidomide | 18 Years - 75 Years | University of Arkansas | |
| First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade | NCT01215344 | Multiple Myelom... | VELCADE Lenalidomide Dexamethasone DVT prophylaxis Bisphosphonates Liposomal doxor... Dexamethasone | 18 Years - 70 Years | Vanderbilt-Ingram Cancer Center | |
| Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients | NCT00984828 | Multiple Myelom... | velcade | 18 Years - 65 Years | Shanghai Jiao Tong University School of Medicine | |
| Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients | NCT00500422 | Solid Tumors | Doxil Gemcitabine Velcade | - | M.D. Anderson Cancer Center | |
| A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib | NCT00706953 | Multiple Myelom... | bortezomib; peg... | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) | NCT00311337 | Multiple Myelom... | bortezomib | 18 Years - | University of Wuerzburg | |
| Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro | NCT01472627 | Multiple Myelom... | Blood draws | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma | NCT02195479 | Multiple Myelom... | Velcade Melphalan Prednisone Daratumumab IV Dexamethasone Daratumumab SC | 18 Years - | Janssen Research & Development, LLC | |
| Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia | NCT01125293 | Waldenstrom's M... | Everolimus Rituximab Bortezomib | 18 Years - | Dana-Farber Cancer Institute | |
| Study of Combination PS-341 and Thalidomide in Multiple Myeloma | NCT00083460 | Multiple Myelom... | PS-341 Thalidomide Dexamethasone | 18 Years - | University of Arkansas | |
| Bevacizumab and Bortezomib in Patients With Advanced Malignancy | NCT00428545 | Advanced Malign... Lymphoma Myeloma Solid Tumors | Bevacizumab Bortezomib | - | M.D. Anderson Cancer Center | |
| Velcade in Myelodysplastic Syndrome - Pilot Study | NCT00440076 | MDS | Velcade | 18 Years - 75 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma | NCT01484626 | Multiple Myelom... | Bendamustine | 18 Years - | Loyola University | |
| Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma | NCT02145715 | Multiple Myelom... | Velcade Thalidomide Dexamethasone Panobinostat | 18 Years - | University of Leeds | |
| Optimising Renal Outcome in Myeloma Renal Failure | NCT02424851 | Multiple Myelom... Chronic Kidney ... | Bortezomib Thalidomide Bendamustine Dexamethasone | 18 Years - | Oxford University Hospitals NHS Trust | |
| A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma | NCT03234972 | Multiple Myelom... | Daratumumab Velcade Dexamethasone | 18 Years - | Janssen Research & Development, LLC | |
| Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma | NCT00580320 | Melanoma Soft Tissue Sar... Parathyroid Car... Small Cell Carc... Carcinoid Tumor... | Dacarbazine and... | 18 Years - | Virginia Commonwealth University | |
| An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function | NCT00718640 | Multiple Myelom... | Dexamethasone Bortezomib | 18 Years - | Janssen-Ortho Inc., Canada | |
| Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults | NCT02535806 | Acute Lymphobla... Lymphoblastic L... | Velcade Methotrexate Methotrexate / ... Dexamethasone Mitoxantrone Vincristine Pegaspargase | 1 Year - 39 Years | Children's Mercy Hospital Kansas City | |
| Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation | NCT02312102 | Myelodysplastic... Acute Myeloid L... | Lenalidomide Velcade | 18 Years - | Massachusetts General Hospital | |
| Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM | NCT01114282 | Multiple Myelom... | velcade Pralatrexate | 18 Years - | Stanford University | |
| A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma | NCT00636792 | Follicular Lymp... | VELCADE Bendamustine Rituximab | 18 Years - | Millennium Pharmaceuticals, Inc. | |
| Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | NCT00337506 | Multiple Myelom... | Dexamethasone velcade | 18 Years - 75 Years | Nantes University Hospital | |
| Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas | NCT00374699 | Peripheral T-Ce... Non-Hodgkin Lym... | Velcade | 18 Years - 65 Years | Samsung Medical Center | |
| A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma | NCT00516191 | Multiple Myelom... | Liposomal Doxor... | 18 Years - | University of California, San Francisco | |
| Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma | NCT03710603 | Multiple Myelom... | Daratumumab velcade Lenalidomide dexamethasone | 18 Years - 70 Years | Stichting European Myeloma Network | |
| Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma | NCT00169468 | B Cell Lymphoma | Rituximab -CHOP... | 18 Years - 80 Years | Lymphoma Study Association | |
| Study of Bortezomib in Combination With Cyclophosphamide and Rituximab | NCT00958256 | Mantle Cell Lym... Lymphoma | Bortezomib Rituximab Cyclophosphamid... Mesna G-CSF | 18 Years - 85 Years | M.D. Anderson Cancer Center | |
| Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab | NCT00850499 | Follicular Lymp... | fludarabine rituximab VELCADE | 18 Years - | Millennium Pharmaceuticals, Inc. | |
| A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma | NCT02195479 | Multiple Myelom... | Velcade Melphalan Prednisone Daratumumab IV Dexamethasone Daratumumab SC | 18 Years - | Janssen Research & Development, LLC | |
| A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region) | NCT03217812 | Multiple Myelom... | Velcade Melphalan Prednisone Daratumumab | 18 Years - | Janssen Research & Development, LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
